Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 10/20 | 0.46 |
| ▸ | NCF1 | P14598 | 6/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985738 | 0.90 | CA12 (0.50) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL22491568 | 0.86 | APP (0.59) | KDM4EMAPTAPPMAOB | |
| SCHEMBL12745131 | 0.83 | KDM4E (0.56) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL31498483 | 0.83 | KDM4E (0.56) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL22491503 | 0.81 | MAOB (0.53) | KDM4EMAPK1TDP1MAPTRAB9A | |
| SCHEMBL4063865 | 0.81 | NCF1 (0.57) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL6542929 | 0.79 | CA12 (0.50) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL7126896 | 0.79 | AGXT (0.46) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL5750884 | 0.78 | CYP2A6 (0.46) | KDM4EMAPK1TDP1NPC1MAPT | |
| SCHEMBL10458381 | 0.78 | CA12 (0.59) | KDM4EMAPK1TDP1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (PA) | 2010-08-26 | — | — | US | disclosed |
| EP-2144916-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | The Trustees of the University of Pennsylvania (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008124812-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | APP, PSEN1, PSEN2 | KDM4E 3675/4885MAPK1 3496/4885TDP1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.